Medical innovators, inventors, and entrepreneurs are registering now for the American International Medical Summit on Biotherapeutics and Medical Designs (AIMS on BioDesign), to be held September 18-20, 2006 in Atlanta, Ga. The summit will focus on endovascular innovations in its inaugural year.
With over 800 physicians, inventors, lawyers, venture capitalists, and company representatives from all over the world expected to attend, AIMS promises to be one of the premiere health sciences industry events of 2006.
Emory University's Woodruff Health Sciences Center is organizing and sponsoring the meeting, with participation by Georgia Tech, the Medical College of Georgia, and the University of Georgia College of Pharmacy.
Emory cardiothoracic surgeon and director of the Emory Center for Device Innovation Omar Lattouf, MD, PhD, says the summit will be a "must attend" meeting for clinical innovators and corporate leaders in the medical device and drug industry, as well as venture capitalists and investors in health care technologies.
"Attendees will be able to meet academic thought leaders in the emerging medical device and bioengineering field," says Dr. Lattouf, chair of the summit.
Robert Guyton, MD, professor and chief of cardiothoracic surgery, Emory University School of Medicine, and co-chair of the summit says, "This meeting of the minds is an expression of our commitment to help break down the barriers that have kept academic scientists and physician-researchers from taking their innovations and ideas to the marketplace, where they can reach patients and their medical care-givers."
"Emory is an established leader in innovations in cardiology and cardiothoracic surgery regionally, nationally, and internationally and is taking new steps to turn innovations into inventions and bring the needed investment resources to translate such inventions into patient-serving solutions," explains Dr. Guyton.
The 2006 summit will provide educational and networking opportunities to support the growing collaboration between industry, investors, and academic institutions in the health science sector focusing on endovascular intervention in cardiology, cardiac and vascular surgery, interventional radiology, interventional neurovascular therapy, and critical care medicine.
Those attending the summit will have the opportunity to:
-Identify pioneering trends and emerging technologies in medical devices and therapeutics.
-Learn how to navigate the complex process of intellectual development from ideas to commercialization.
-Learn how to protect intellectual property, finance research and development, and recruit financing from venture capital and angel investment groups.
-Foster new opportunities to collaborate on inventions throughout the commercialization process.
-Showcase new technologies at all stages of development to experts in research, development, funding, and commercialization.
Michael M.E. Johns, MD, executive vice president for health affairs at Emory University, CEO of the Woodruff Health Sciences Center, and chairman of the board for Emory Healthcare, is a key supporter of the event. "This summit will demonstrate Emory's commitment to the worldwide advancement of global initiatives in biodesign as it directly applies to patient care," says Dr. Johns.
AIMS on Biodesign will include five key sessions:
-Emerging global trends in medical device and bioscience technologies
-Emerging start-ups companies and promising new technologies
-The road to success: views from industry leaders
-Protecting your intellectual assets
-Promising proposals vs. funding failures, the investor's perspective
For more information on the summit and instructions on how to register, see www.aimsbiodesign.org.